Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

National Healthcare (NHC) Cash & Equivalents (2016 - 2025)

National Healthcare (NHC) has disclosed Cash & Equivalents for 16 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 7.41% year-over-year to $18.1 million, compared with a TTM value of $18.1 million through Dec 2025, down 7.41%, and an annual FY2025 reading of $18.1 million, down 7.41% over the prior year.
  • Cash & Equivalents was $18.1 million for Q4 2025 at National Healthcare, down from $19.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $136.2 million in Q2 2024 and bottomed at $18.1 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $73.6 million, with a median of $77.1 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 125.34% in 2023, then plummeted 86.67% in 2025.
  • Year by year, Cash & Equivalents stood at $107.6 million in 2021, then crashed by 45.48% to $58.7 million in 2022, then surged by 82.51% to $107.1 million in 2023, then tumbled by 81.73% to $19.6 million in 2024, then fell by 7.41% to $18.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for NHC at $18.1 million in Q4 2025, $19.7 million in Q3 2025, and $18.2 million in Q2 2025.